Joel Beatty
Stock Analyst at Baird
(4.12)
# 373
Out of 4,880 analysts
202
Total ratings
41.36%
Success rate
16.76%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Neutral | $7 → $9 | $9.09 | -0.94% | 5 | Jun 20, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $126.67 | +14.47% | 6 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $21.36 | +45.13% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $19.19 | +25.07% | 3 | May 16, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $8 → $4 | $2.25 | +77.78% | 4 | May 13, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $17.96 | +178.40% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $542.47 | +25.35% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $13.95 | +107.89% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $48.59 | +35.83% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $109.44 | +41.63% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $7.22 | -3.05% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $102.97 | +57.33% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $28.98 | +41.48% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $2.87 | +249.04% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $6.68 | +139.52% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $3.85 | +315.58% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $43.17 | +69.10% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $21.19 | +51.01% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $26.58 | +182.17% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $6.41 | +71.61% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.65 | +324.24% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $56.19 | +15.68% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $128.34 | -1.04% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $36.26 | +98.57% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.23 | +8,595.65% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.38 | +226.09% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $11.71 | +113.49% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.30 | +2,900.00% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $8.82 | +217.46% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.09 | +665.55% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.43 | -48.56% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.17 | +3,660.68% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $16.09 | +260.47% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $21.13 | +13.58% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $12.99 | +38.57% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.51 | +70.94% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.29 | +2,303.10% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.11 | +447.95% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $322.06 | -45.66% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.70 | +198.19% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $17.71 | +509.82% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $39.95 | +95.24% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $10.49 | +853.29% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $16.81 | +613.86% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $1.86 | +24,093.55% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.00 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $6.61 | +126.93% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.57 | +20,952.63% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $5.60 | +239.29% | 3 | Nov 10, 2017 |
Sage Therapeutics
Jun 20, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $9.09
Upside: -0.94%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $126.67
Upside: +14.47%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $21.36
Upside: +45.13%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $19.19
Upside: +25.07%
Editas Medicine
May 13, 2025
Maintains: Outperform
Price Target: $8 → $4
Current: $2.25
Upside: +77.78%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $17.96
Upside: +178.40%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $542.47
Upside: +25.35%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $13.95
Upside: +107.89%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $48.59
Upside: +35.83%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $109.44
Upside: +41.63%
May 7, 2025
Maintains: Neutral
Price Target: $8 → $7
Current: $7.22
Upside: -3.05%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $102.97
Upside: +57.33%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $28.98
Upside: +41.48%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $2.87
Upside: +249.04%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $6.68
Upside: +139.52%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $3.85
Upside: +315.58%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $43.17
Upside: +69.10%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $21.19
Upside: +51.01%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $26.58
Upside: +182.17%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $6.41
Upside: +71.61%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.65
Upside: +324.24%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $56.19
Upside: +15.68%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $128.34
Upside: -1.04%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $36.26
Upside: +98.57%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.23
Upside: +8,595.65%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.38
Upside: +226.09%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $11.71
Upside: +113.49%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.30
Upside: +2,900.00%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $8.82
Upside: +217.46%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.09
Upside: +665.55%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.43
Upside: -48.56%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.17
Upside: +3,660.68%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $16.09
Upside: +260.47%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $21.13
Upside: +13.58%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $12.99
Upside: +38.57%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.51
Upside: +70.94%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.29
Upside: +2,303.10%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.11
Upside: +447.95%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $322.06
Upside: -45.66%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.70
Upside: +198.19%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $17.71
Upside: +509.82%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $39.95
Upside: +95.24%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $10.49
Upside: +853.29%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $16.81
Upside: +613.86%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $1.86
Upside: +24,093.55%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.00
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $6.61
Upside: +126.93%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.57
Upside: +20,952.63%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $5.60
Upside: +239.29%